Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?

Hepatology

Volumn 63, Issue 3, 2016, Pages 1014-1025

  Yao, Francis Y ^a   Fidelman, Nicholas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGY; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR DOWN STAGING; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; LIVER; LIVER NEOPLASMS; NEOADJUVANT THERAPY; PATHOLOGY; PATIENT SELECTION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION;

EID: 84973521541     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28139     Document Type: Review

References (49)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
2. Mazzaferro V, Regalia E, Doci R, Bhoori S, Schiavo M, Mariani L, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
3. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011;11:2362-2371.
4. Salgia RJ, Goodrich NP, Marrero JA, Volk ML. Donor factors similarly impact survival outcome after liver transplantation in hepatocellular carcinoma and non-hepatocellular carcinoma patients. Dig Dis Sci 2014;59:214-219.
5. Kim WR, Smith JM, Skeans MA, Schladt DP, Schnitzler MA, Edwards EB, et al. OPTN/SRTR 2012 annual data report. Am J Transpl 2014;14(Suppl.):69-96.
6. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma. Liver Transpl 2011;17(Suppl. 2):S81-S89.
7. Yao FY. Liver transplantation for hepatocellular carcinoma: Beyond Milan criteria. Am J Transplant 2008;8:1962-1969.
8. Bittermann T, Niu B, Hoteit MA, Goldberg D. Waitlist priority for hepatocellular carcinoma beyond Milan criteria: a potentially appropriate decision without a structured approach. Am J Transpl 2014;14:79-87.
9. Mehta N, Yao FY. Moving past "one size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplant. Liver Transpl 2013;19:1055-1058.
10. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010;16:925-929.
11. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-994.
12. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein >1000 ng/mL as an exclusion criterion for liver transplant in patients with hepatocellular carcinoma meeting Milan criteria. Liver Transpl 2014;20:945-951.
13. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260-1267.
14. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13:272-279.
15. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumor progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013;19:1108-1118.
16. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
17. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:249-251.
18. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
19. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
20. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015;61:1056-1065.
21. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013;266:376-382.
22. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the downstaging of hepatocellular carcinoma? Liver Transpl 2011(Suppl. 2):S109-S116.
23. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burrough AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-430.
24. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
25. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma: validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918.
26. Lo CM. Downstaging of hepatocellular carcinoma before transplantation: an advance in therapy or just another selection criterion? Am J Transpl 2008;8:2485-2486.
27. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of pre-operative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688-701.
28. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563.
29. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617-625.
30. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ III, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827.
31. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transpl 2008;8:2547-2557.
32. De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transpl 2009;9:1158-1168.
33. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transpl 2009;9:1920-1928.
34. Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, et al. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2009;31:415-423.
35. Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010;16:289-299.
36. Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H, Ruef R, et al. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. J Vasc Interv Radiol 2013;24:1613-1622.
37. Yao FY, Mehta N, Flemming JA, Hameed B, Fix O, Hirose R, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-1977.
38. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:11-22.
39. Lammer J, Malagari K, Vogl T, Pilleul F, Deys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
40. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005;16:195-203.
41. Garwood ER, Fidelman N, Hoch SE, Kerlan RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013;19:164-173.
42. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Hepatology 2013;57:2261-2273.
43. Terzi E, Terenzi L, Venerandi L, Croci L, Renzulli M, Mosconi C, et al. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series. Dig Dis 2014;32:711-716.
44. Kwan SW, Fidelman N, Ma E, Kerlan RK Jr, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012;18:727-736.
45. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013;19:1343-1353.
46. Hakeem AR, Young RS, Marangoni G, Lodge JPA, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:987-999.
47. Mehta N, Fidelman N, Sarkar M, Yao FY. Infiltrative hepatocellular carcinoma: predictors of survival and impact of tumor-directed therapy. Clin Gastroenterol Hepatol 2013;11:572-578.
48. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transpl 2011;11:2031-2035.
49. Mehta N, Guy J, Frenette CT, Sarkar M, Osorio RW, Minteer WB, et al. Multicenter study of down-staging of hepatocellular carcinoma to within Milan criteria before liver transplantation. Hepatology 2014;60(Suppl.):253A.